Evidence map›Paper›PMID 41928160›Full record

ArticleBMC cancer2026

Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention ('REVITALIZE') to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol.

Joanna J Arch, Hajime Uno, Hanneke Poort, Elizabeth Slivjak, Madeline S Nealis, Hannah Park, Irene Wang, Sarah R Genung, Angel Cronin, David J Andorsky and 6 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06710548 (Randomized Trial of REVITALIZE), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06710548 narecruitingnot on this map

Randomized Trial of REVITALIZE: A Telehealth Intervention to Reduce Fatigue Interference Among Adults With Advanced Ovarian Cancer on PARP Inhibitors

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2025 to 2029Enrolled240ConditionsOvarian Cancer, Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal CancerArmsREVITALIZE Intervention, Educational Materials
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Joanna J ArchDepartment of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA. Joanna.Arch@colorado.edu.
Hajime UnoDepartment of Medical Oncology, Division of Population Sciences, and Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
Hanneke PoortRadboud University Medical Center, Nijmegen, Netherlands.
Elizabeth SlivjakDepartment of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA.
Madeline S NealisDepartment of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA.
Hannah ParkDepartment of Medical Oncology, Division of Population Sciences, and Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
Irene WangDepartment of Medical Oncology, Division of Population Sciences, and Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah R GenungDepartment of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA.
Angel CroninDepartment of Medical Oncology, Division of Population Sciences, and Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
David J AndorskyRocky Mountain Cancer Centers, Boulder, CO, USA.
Laura J HavrileskyDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke School of Medicine, Durham, NC, USA.
Richard T PensonDivision of Medical Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Varvara MazinaDivision of Medical Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
Page WidickDivision of Medical Oncology, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Carolyn LefkowitsDivision of Gynecologic Oncology, University of Colorado Anschutz School of Medicine, Aurora, CO, USA.
Alexi A WrightDepartment of Medical Oncology, Division of Population Sciences, and Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA. Alexi_Wright@dfci.harvard.edu.

Funding

Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitorsR01CA289547 · NCI · DANA-FARBER CANCER INST · PI Joanna J Arch, Alexi A Wright · 2024 to 2026
$2.1M
NCI NIH HHS R01 CA289547NIH HHS R01CA289547
6 · The paper itself

Abstract

backgroundIn the era of precision oncology, patients with advanced cancer are often living longer but are enduring years of fatiguing treatment. Fatigue is among the most common, chronic, and under-addressed side effects of advanced cancer treatment, and can lead to dose reductions, treatment interruptions, and discontinuation. Oral PolyADP-ribose polymerase (PARP) inhibitors have revolutionized the treatment of advanced ovarian cancer but are often accompanied by clinically-significant fatigue, and evidence-based treatments to cope with this side effect remain limited. A pilot trial suggests that telehealth acceptance and commitment therapy (ACT), a variant of cognitive behavioral therapy based on acceptance, mindfulness, and personal values, has potential to improve fatigue interference (i.e. disrupting activity and quality of life) among ovarian cancer patients on maintenance PARP inhibitors. This study protocol describes a fully-powered randomized controlled trial (RCT) of an innovative, remotely-delivered ACT intervention (‘REVITALIZE’) that aims to improve fatigue outcomes and PARP inhibitor adherence.

methodsThis two-armed, prospective RCT randomizes 240 adults with advanced ovarian cancer who report moderate to severe fatigue while on PARP inhibitors 1:1 to either REVITALIZE or education-enhanced usual care. The REVITALIZE intervention includes eight weekly one-hour individual sessions delivered via videoconference, plus two booster sessions at one- and two-month intervals thereafter. Participants, recruited from both academic and community cancer care sites across three U.S. regions, will complete assessments at baseline, mid-intervention, post-intervention, and 20 and 28-week follow-up (FU). The primary patient-reported outcome is change in fatigue interference from baseline to week 20 (FU1). Secondary patient-reported outcomes include fatigue severity, catastrophizing, self-efficacy, and quality of life. The primary behavioral outcome is monthly PARP inhibitor adherence, assessed by wireless medication adherence monitors; dose interruptions, reductions, and persistence will also be evaluated using adherence monitors and medical chart review. DISCUSSION: This paper describes a RCT that will evaluate the efficacy of the telehealth REVITALIZE intervention for improving fatigue-related outcomes and medication adherence among adults with advanced ovarian cancer taking PARP inhibitors. Findings will inform clinical practice and supportive care for adults with advanced ovarian cancer receiving treatments that cause fatigue.

trial registrationClinicaltrials.gov NCT06710548 on November 29, 2024.

Indexed as

Acceptance and Commitment TherapyFatigueOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsFemaleHumansProspective StudiesQuality of LifeRandomized Controlled Trials as TopicTelemedicinePoly(ADP-ribose) Polymerase InhibitorsAcceptance and commitment therapyCancerFatigueMaintenance treatmentMedication adherenceOvarian cancerPARP inhibitorsQuality of life

Identifiers

PMID41928160
PMCPMC13169764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.